Showing 3081-3090 of 6035 results for "".
- Genentech/Roche Initiate First Diabetic Macular Edema Phase 3 Trial of the Port Delivery System with Ranibizumabhttps://modernod.com/news/genentech-roche-initiate-first-diabetic-macular-edema-phase-3-trial-of-the-port-delivery-system-with-ranibizumab/2477233/Genentech and Roche have initiated a new phase 3 clinical trial investigating the Port Delivery System with ranibizumab (PDS) in people with diabetic macular edema (DME). The PDS is an investigational first-of-its-kind refillable eye implant designed to continuously release a customized formulati
- Staar Surgical Gains Supplemental Lens Approval for EVO Visian ICL to Target Post-Cataract Market Opportunityhttps://modernod.com/news/staar-surgical-gains-supplemental-lens-approval-for-evo-visian-icl-to-target-post-cataract-market-opportunity/2477226/Staar Surgical announced it has gained CE Mark approval for use of its ICL as a supplemental or “piggyback” lens in post-cataract IOL surgery patients (pseudophakics). A supplemental EVO ICL is placed in front of the cataract IOL lens in post-cataract patients, just like the EVO ICL is placed in
- Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseaseshttps://modernod.com/news/exonate-announces-collaboration-with-janssen-to-develop-a-new-eye-drop-for-the-treatment-of-retinal-vascular-diseases/2477223/Exonate, an early stage biotechnology company, announced that it has entered into a strategic collaboration agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Through the collaboration, Exonate will work with Janssen Research & Development scientists to develop an
- Watchdog: NHS Delays Responsible for Glaucoma Patients Going Blindhttps://modernod.com/news/watchdog-nhs-delays-responsible-for-glaucoma-patients-going-blind/2477221/Long delays to treatment on the NHS have been responsible for glaucoma patients losing their sight, a safety watchdog in the UK has warned, according to a report in Independent. The
- US Cancer Death Rates Are Dropping at the Fastest Pace on Recordhttps://modernod.com/news/us-cancer-death-rates-are-dropping-at-the-fastest-pace-on-record/2477215/The cancer death rate in the U.S. fell by the most on record as advances in treatments for lung tumors like video-assisted surgery helped prolong the lives of patients, according to a Bloomberg
- Acucela Announces Publication Assessing the Role of Emixustat Hydrochloride in Retinal Degeneration Treatmenthttps://modernod.com/news/acucela-announces-publication-assessing-the-role-of-emixustat-hydrochloride-in-retinal-degeneration-treatment/2477209/Acucela announced the publication of an article concerning the company’s investigational drug candidate, emixustat hydrochloride (emixustat), in the scientific journal Drug Discovery Today. The published article, “Pharmacotherapy for Metabolic and Cellular Stress in Degenerative R
- Bausch + Lomb Launches Expanded Parameters for Biotrue ONEday for Astigmatism Daily Disposable Contact Lenseshttps://modernod.com/news/bausch-lomb-launches-expanded-parameters-for-biotrue-oneday-for-astigmatism-daily-disposable-contact-lenses/2477205/Bausch + Lomb announced the US launch of expanded parameters for Biotrue ONEday for Astigmatism daily disposable contact lenses. The expansion will increase the toric parameter range by more than 60%, offering eye care professionals and their astigmatic patients the largest parameter offering of
- EnChroma Introduces Line of Lenses for Low Vision and Age-Related Eye Conditionshttps://modernod.com/news/enchroma-introduces-line-of-lenses-for-low-vision-and-age-related-eye-conditions/2477199/EnChroma unveiled the “EnChroma Lx Series for Low Vision and Age-Related Eye Conditions,” a product line to address a rapidly growing category of visual challenges worldwide. The new line will be showcased at the Opti Munich 2020 International Trade Show for Optics and Design t
- Market Scope: Ophthalmic Deals Surge in 2018-2019; Most Transactions Involve New Ventureshttps://modernod.com/news/market-scope-ophthalmic-deals-surge-in-2018-2019-most-transactions-involve-new-ventures/2477195/Ophthalmic deals garnered over $9 billion from January 2018 through October 2019, driven largely by dry eye and retina related fundraising. Over 100 transactions occurred during this period, and over 80 percent of transaction are categorized as new ventures. The Novartis acquisition of Xii
- Bausch + Lomb Initiates Clinical Trial Evaluating New Cohesive Ophthalmic Viscosurgical Device (OVD)https://modernod.com/news/bausch-lomb-initiates-clinical-trial-evaluating-new-cohesive-ophthalmic-viscosurgical-device-ovd/2477174/Bausch + Lomb announced that it has initiated a clinical trial evaluating the safety and efficacy of a new cohesive ophthalmic viscosurgical device (OVD) intended to provide surgeons with a new option in the continuum of cohesive and dispersive viscoelastics. “This is the second new OVD th